MIMEDX GROUP INC (MDXG)
Health Care · Advanced wound care / tissue-based biologics · NASDAQ
MiMedx develops and distributes advanced wound care biologics including human placental allografts and expanding xenograft/collagen products to treat chronic and hard-to-heal wounds across surgical and clinical settings.
What MIMEDX GROUP INC does
MiMedx is a leading provider of advanced wound care products, including human placental allografts, xenografts, and distributed wound care modalities. The company manufactures and distributes its products through proprietary processes like the PURION® process for use in wound care, surgical, and burn applications to help clinicians manage chronic and hard-to-heal wounds. The company has historically focused on placental biologics but has expanded its portfolio to include animal-derived products and other wound care modalities through partnerships and distribution agreements. MiMedx products are used across hospitals and surgical specialties to support the healing process when patients are not responding to conventional wound treatments.
Themes: ["Wound care biologics","Advanced wound care (AWC)","Placental allografts / human tissue products","Surgical wound management","Chronic wound healing","Xenografts / animal-derived products"]
Fundamentals
- Price$4.14 as of 2026-07-09 close
- Market cap$617M as of 2026-07-10
- 1-year return-39.1% as of 2026-07-09 close
- P/E20.09 as of 2026-07-10
- Net margin+7.9% as of 2026-07-10
- Gross margin+81.0% as of 2026-07-10
- ROE+12.9% as of 2026-07-10
- Debt / equity0.07 as of 2026-07-10
- Revenue growth (YoY)+10.5% as of 2026-07-10
- Revenue CAGR (3y)+16.1% SEC XBRL
- Beta1.46 as of 2026-07-10
Key risks (from latest filing)
["Significant decline in net sales (Q1 2026: $59.0M vs Q1 2025: $88.2M, down 33%) linked to changes in Medicare reimbursement for skin substitutes","Portfolio transition and expansion uncertainty—company is rapidly shifting from exclusive placental allografts to distribution partnerships for multiple modalities, with execution risk on commercialization","Accumulated deficit of $53.5M and recent operating loss ($16.0M operating loss in Q1 2026 vs. $8.3M operating income in Q1 2025) despite profitable full-year results, indicating cash burn and near-term profitability pressure"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.